$51.46Peak — highest point inside the window, not a realized return
$45.16Window close — end-of-window price, context only
What happened
Target reached
Reached its target in 15 days.
At window close
+7%
realized, from the publication price to the last close inside the window
Peak gain
+21.9%
peak, from the publication price — not a realized return
S&P 500, same window
+5.9%
SPY over the identical days, dividend-adjusted
Window close
$45.16
last close inside the window, ended September 8, 2026
Peak price
$51.46
peak on July 29, 2026 — not a realized return
Days to target
15
The thesis — published June 10, 2026
Predicted growth
+12%
over the measurement window
Target price
$46.69
the price the thesis aimed for
Entry zone
$40.46 – $42.17
the fair-value band we waited for
Price at publication
$42.22
published June 10, 2026
Confidence
83%
how strongly the data lined up
Timeframe
Short-term (0–3 months)
Novo Nordisk looks like steady growth with near-term reasons to pay attention. New prescription news for the Wegovy pill shows the obesity business is still growing even with more competitors. Strong profit margins and a reasonable price make the stock more resilient in choppy markets. The setup favors buying on a controlled pullback while buying interest supports the three-month view.
Primary drivers
Wegovy pill use shows obesity franchise is expanding
Healthcare demand offers protection in weak markets
Healthy profit margins and fair price support stability
A pullback offers a calmer entry than chasing strength
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.